ATLANTA, Aug. 9, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the appointment of Jack W. Callicutt to the position of Vice President and Chief Financial Officer, effective August 6, 2007.
Mr. Callicutt will lead the Company's financial and administrative activities, including interaction with capital markets and investor relations. As a member of the senior management team, Mr. Callicutt will play a key role in shaping corporate strategy. He will also help to assure that the Company has the necessary economic resources to realize its vision for its pipeline of three late stage clinical development assets, which is critical to create profitable growth and shareholder value.
"Jack's leadership, financial management experience, and demonstrated deal-making capabilities in the pharmaceutical industry make him ideal for this role," said Dr. Harold H. Shlevin, President and Chief Executive Officer of Tikvah Therapeutics, Inc. "I am looking forward to partnering closely with Jack and am thrilled to add an individual of Jack's caliber to our management team."
Mr. Callicutt has over 18 years of public and private company experience and more than a decade of audit, tax, and SEC registrant experience with a major audit firm. He was most recently Senior Vice President and Chief Financial and Accounting Officer at Corautus Genetics Inc. where he was responsible for all areas in finance, accounting, treasury, risk management, and administration for Corautus, which is publicly traded on Nasdaq. Mr. Callicutt joined Corautus in September 2003 and during his tenure completed several equity and convertible debt offerings totaling over $50 million and negotiated and closed the recent merger of Corautus with Via Pharmaceuticals, Inc. Prior to joining Corautus Genetics, Mr. Callicutt spent 14 years with Deloitte, a global accounting firm.
"I am excited by Tikvah's current therapeutic development pipeline and am impressed by the quality of the team that Dr. Shlevin has assembled," said Jack W. Callicutt. I look forward to helping facilitate growth and financial stability in positioning Tikvah for success."
Mr. Callicutt is a Certified Public Accountant and graduated, cum laude, from Delta State University.
Bringing Hope to Life....(sm)
About Tikvah Therapeutics, Inc.
Atlanta-based Tikvah Therapeutics, Inc. focuses on exploring new uses for late-stage pharmaceutical compounds in selected therapeutic indications of central nervous system diseases, including neurology and psychiatry disorders. Its focus is on new therapeutic uses that have been confirmed in multiple, clinical proof-of-concept studies. This strategy shortens product development timelines and substantially decreases the risk associated with the research and development efforts. A second prong of its strategy is to focus on specialized products with multiple stepping-stone indications and strong patent protections, thus helping to ensure long product life cycles and manageable commercial risk. Tikvah Therapeutics was founded by Paramount BioSciences, LLC. For additional information about Tikvah Therapeutics, please visit www.tikvahtherapeutics.com.
The Tikvah Therapeutics, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3966
Note to Editor: A photo of Mr. Callicutt is available upon request.
"TIKVAH THERAPEUTICS, INC.," "Bringing Hope to Life," and the above logo design are trademarks of Tikvah Therapeutics, Inc., Atlanta, Georgia USA